|Bid||91.21 x 800|
|Ask||91.70 x 800|
|Day's Range||88.38 - 92.22|
|52 Week Range||37.92 - 127.77|
|PE Ratio (TTM)||23.33|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Enanta Pharmaceuticals (NASDAQ:ENTA) has been in the news recently. Before I get around to what’s been happening with ENTA stock recently, it may help to get a broader understanding of how the company operates and what exactly it does. What used to be a fairly typical model, where you discover a drug, run it through the various drug trials, build a marketing plan and sell the drug, has now become much more focused.
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 1.04% and 1.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Watertown, Massachusetts-based company said it had profit of 97 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and 2016 by the S&P 500. The market cap had gained 188% between 2013 and 2017.
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.